This transcript has been edited for clarity.
Christopher V. DeSimone, MD, PhD: Hello, and welcome back to the Mayo Clinic–Medscape video series.
I'm Christopher DeSimone, a cardiologist and medical director of CV marketing at the Mayo Clinic in Rochester, Minnesota. Today I'll be discussing hypertrophic cardiomyopathy (HCM) with my colleague, Steve Ommen, a consultant, professor of medicine, and expert in this area. Welcome, Dr Ommen.
Steve R. Ommen, MD: Thanks, Chris.
SCD and New Guidelines
DeSimone: The new American Heart Association (AHA)/American College of Cardiology (ACC) guidelines on HCM are out. You played an integral role in shaping them and served as the lead author. One of the takeaways from these guidelines relates to changes in sudden cardiac death screening. How has that evolved over the years?
Ommen: That's an important question. Historically, if you go back to the prior guidelines in 2011, we basically just counted up a series of risk factors. Anyone who had two or more risk factors was eligible for an implantable cardioverter-defibrillator, there was lots of debate and controversy about what to do with patients with one risk factor, and patients who had zero risk factors were reassured.
We tried to put some weighting around the various risk factors
'Smart' Stethoscope Spots Peripartum Cardiomyopathy
Restrictive Cardiomyopathy
Imaging in Hypertrophic Cardiomyopathy
COMMENTARY
Managing Hypertrophic Cardiomyopathy: New Guidelines and Drugs
Steve R. Ommen, MD; Christopher V. DeSimone, MD, PhD
DisclosuresAugust 02, 2021
Editorial Collaboration
Medscape &
This transcript has been edited for clarity.
Christopher V. DeSimone, MD, PhD: Hello, and welcome back to the Mayo Clinic–Medscape video series.
I'm Christopher DeSimone, a cardiologist and medical director of CV marketing at the Mayo Clinic in Rochester, Minnesota. Today I'll be discussing hypertrophic cardiomyopathy (HCM) with my colleague, Steve Ommen, a consultant, professor of medicine, and expert in this area. Welcome, Dr Ommen.
Steve R. Ommen, MD: Thanks, Chris.
SCD and New Guidelines
DeSimone: The new American Heart Association (AHA)/American College of Cardiology (ACC) guidelines on HCM are out. You played an integral role in shaping them and served as the lead author. One of the takeaways from these guidelines relates to changes in sudden cardiac death screening. How has that evolved over the years?
Ommen: That's an important question. Historically, if you go back to the prior guidelines in 2011, we basically just counted up a series of risk factors. Anyone who had two or more risk factors was eligible for an implantable cardioverter-defibrillator, there was lots of debate and controversy about what to do with patients with one risk factor, and patients who had zero risk factors were reassured.
We tried to put some weighting around the various risk factors
© 2021 Mayo Clinic
Cite this: Managing Hypertrophic Cardiomyopathy: New Guidelines and Drugs - Medscape - Aug 02, 2021.
Tables
Authors and Disclosures
Authors and Disclosures
Authors
Steve R. Ommen, MD
Professor of Medicine, Consultant, Mayo Clinic School of Medicine, Rochester, Minnesota
Disclosure: Steve R. Ommen, MD, has disclosed no relevant financial relationships.
Christopher V. DeSimone, MD, PhD
Assistant Professor of Medicine, Senior Associate Consultant, Mayo Clinic School of Medicine, Rochester, Minnesota
Disclosure: Christopher DeSimone, MD, PhD, has disclosed no relevant financial relationships.